PDCD1 and neoplasm: To assess the mechanisms by which CV8102 mediates its anti-tumoral activity and boosts the anti-tumoral effects of anti-PD-1, RNA-Seq analysis of the CT26 tumors, which included the tumor cells, stromal cells and immune cells was performed 5 h after the second treatment with 100 μg CV8102, 200 μg anti-PD-1 antibody, or both treatments combined.